Beranda › Kanker Payudara › Rhode Island
Uji klinis Kanker Payudara di Rhode Island
14 studi untuk Kanker Payudara mencari peserta di lokasi di Rhode Island.
Kota di Rhode Island
Teks studi resmi (Bahasa Inggris)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Rhode Island Hospital, Providence
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Smilow Cancer Hospital - Westerly, Westerly
Menerima pesertaFase 3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06103864A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Rhode Island Hospital, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Women and Infants Hospital, Providence
- Kent Hospital, Warwick
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Menerima pesertaFase 3
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Smilow Cancer Hospital Care center at Westerly, Westerly
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04893109Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Women and Infants Hospital, Providence
Menerima pesertaFase 3
Usia 18 hingga 50 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06748222A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Lifespan Cancer Institute - Rhode Island Hospital, Providence
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
- Kent Hospital, Warwick
- dan 1 lainnya
Menerima pesertaFase 3
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Women & Infants Hospital, Providence
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT06401421SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Okt 2025 · NCT06974604Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.